Acquired Immune Thrombotic Thrombocytopenic Purpura Develops After Vaccination With Coronavac

Nov 17 2025

Researchers from nan Second Affiliated Hospital of Nanjing Medical University, et al. person published a lawsuit study entitled "Acquired immune thrombotic thrombocytopenic purpura (TTP) associated pinch inactivated COVID-19 vaccine CoronaVac". This study was published successful Frontiers of Medicine, Volume 18, Issue 4, 2024.

Acquired immune thrombotic thrombocytopenic purpura (TTP) is simply a uncommon but life-threatening bleeding disorder. Previous studies person reported cases of TTP pursuing management of mRNA- aliases adenoviral vector-based COVID-19 vaccines. However, whether inactivated COVID-19 vaccines (such arsenic CoronaVac) could origin TTP and whether nan symptoms of TTP cases induced by inactivated vaccines are different from those of antecedently reported cases stay unclear. The researchers reported 2 cases of TTP that developed aft vaccination pinch CoronaVac. Both patients developed TTP aft receiving nan 2nd dose of CoronaVac, pinch nary abnormalities observed aft nan first dose. They presented pinch symptoms including fever, neurological abnormalities, renal dysfunction, thrombocytopenia, and hemolysis. Both patients achieved complete remission done respective sessions of plasma speech and immunosuppressive therapy. In addition, nan study analyzed nan incidence of TTP successful Nanjing area from 2019 to 2022. The number of recently diagnosed TTP cases during this play was 11, 6, 16, and 17 respectively. The incidence of TTP decreased successful 2020 and past accrued successful 2021-2022, which is presumably related to nan management of COVID-19 vaccines.

This study is nan first study connected TTP associated pinch inactivated COVID-19 vaccines specified arsenic CoronaVac. The rarity and delayed onset of TTP whitethorn beryllium attributed to nan comparatively milder immune consequence induced by inactivated vaccines. Timely plasma speech is simply a captious curen for specified TTP cases.